Ingalls & Snyder LLC’s Edwards Lifesciences EW Stock Holding History

Ingalls & Snyder LLC’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$300K	Hold	3,750	–	–	0.01%	373
2025 Q4	$320K	Sell	3,750 -150	-4%	-$12.3K	0.01%	359
2025 Q3	$303K	Sell	3,900 -750	-16%	-$58.6K	0.01%	383
2025 Q2	$364K	Sell	4,650 -1,662	-26%	-$124K	0.01%	334
2025 Q1	$457K	Sell	6,312 -412	-6%	-$29.5K	0.02%	305
2024 Q4	$498K	Sell	6,724 -3,463	-34%	-$242K	0.02%	292
2024 Q3	$672K	Sell	10,187 -72	-0.7%	-$5.23K	0.03%	268
2024 Q2	$948K	Sell	10,259 -250	-2%	-$22.1K	0.04%	225
2024 Q1	$1M	Sell	10,509 -114	-1%	-$9.58K	0.04%	219
2023 Q4	$810K	Sell	10,623 -1,090	-9%	-$75.8K	0.04%	231
2023 Q3	$811K	Buy	11,713 +975	+9%	+$78.4K	0.04%	227
2023 Q2	$1.01M	Buy	+10,738	New	+$933K	0.05%	211

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ingalls & Snyder LLC's EW Position: Q1 2026 in Review

Ingalls & Snyder LLC held its Edwards Lifesciences (EW) position steady in Q1 2026 at 3,750 shares worth $300K. The position accounts for 0.01% of the portfolio, ranked #373.

Ingalls & Snyder LLC first reported a position in EW in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.01M in Q2 2023. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Ingalls & Snyder LLC held 3,750 shares of Edwards Lifesciences worth $300K as of Q1 2026.
Ingalls & Snyder LLC left its Edwards Lifesciences share count unchanged in Q1 2026.
Edwards Lifesciences made up 0.01% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #373 holding.
Ingalls & Snyder LLC first reported a position in Edwards Lifesciences in Q2 2023 and has held it in 12 quarters since.
Ingalls & Snyder LLC's Edwards Lifesciences position peaked at $1.01M in Q2 2023.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.